It is time to move forward into the era of Theranostics
Abstract Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy wi...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2018-01-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13550-018-0364-x |
_version_ | 1819068613293768704 |
---|---|
author | Hojjat Ahmadzadehfar Markus Essler |
author_facet | Hojjat Ahmadzadehfar Markus Essler |
author_sort | Hojjat Ahmadzadehfar |
collection | DOAJ |
description | Abstract Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry. |
first_indexed | 2024-12-21T16:36:56Z |
format | Article |
id | doaj.art-7c422f9dcf1249e495d102bc4b4036f7 |
institution | Directory Open Access Journal |
issn | 2191-219X |
language | English |
last_indexed | 2024-12-21T16:36:56Z |
publishDate | 2018-01-01 |
publisher | SpringerOpen |
record_format | Article |
series | EJNMMI Research |
spelling | doaj.art-7c422f9dcf1249e495d102bc4b4036f72022-12-21T18:57:12ZengSpringerOpenEJNMMI Research2191-219X2018-01-01811210.1186/s13550-018-0364-xIt is time to move forward into the era of TheranosticsHojjat Ahmadzadehfar0Markus Essler1Department of Nuclear Medicine, University Hospital BonnDepartment of Nuclear Medicine, University Hospital BonnAbstract Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.http://link.springer.com/article/10.1186/s13550-018-0364-xTheranosticsRadionuclide therapyOncologyFellowship |
spellingShingle | Hojjat Ahmadzadehfar Markus Essler It is time to move forward into the era of Theranostics EJNMMI Research Theranostics Radionuclide therapy Oncology Fellowship |
title | It is time to move forward into the era of Theranostics |
title_full | It is time to move forward into the era of Theranostics |
title_fullStr | It is time to move forward into the era of Theranostics |
title_full_unstemmed | It is time to move forward into the era of Theranostics |
title_short | It is time to move forward into the era of Theranostics |
title_sort | it is time to move forward into the era of theranostics |
topic | Theranostics Radionuclide therapy Oncology Fellowship |
url | http://link.springer.com/article/10.1186/s13550-018-0364-x |
work_keys_str_mv | AT hojjatahmadzadehfar itistimetomoveforwardintotheeraoftheranostics AT markusessler itistimetomoveforwardintotheeraoftheranostics |